Retatrutide
Retatrutide (LY3437943)
Retatrutide is the heavyweight champ of the incretin world right now. Eli Lilly engineered this 39-amino-acid peptide to hit three different receptors at once: GLP-1, GIP, and Glucagon. While semaglutide targets one pathway and tirzepatide hits two, retatrutide's 'triple G' approach pushed clinical trial weight loss past the 24% mark in under a year. We haven't seen anything this potent before outside of bariatric surgery.
Buy Retatrutide at Peptide PalacePurity
99%+
Molecular Weight
4731.33 g/mol
Administration
Subcutaneous injection
Storage
Store lyophilized powder at -20°C for long-term preservation
Mechanism of Action
The GLP-1 and GIP agonism handles the standard incretin duties—crushing appetite, slowing gastric emptying, and sensitizing insulin. But the glucagon receptor agonism is the real party trick here. By stimulating the glucagon receptor, retatrutide actively increases your resting energy expenditure and rapidly oxidizes hepatic fat. You aren't just eating less; you are actively burning more fuel and clearing out a fatty liver.
Sequence:
Tyr-Aib-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-α-Me-Leu-Leu-Asp-Lys-(C20-fatty-diacid-linker)-Ala-Gln-Aib-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 Research Areas
- Extreme obesity and weight management
- Non-alcoholic fatty liver disease (NAFLD) and NASH
- Type 2 diabetes glycemic control
- Resting energy expenditure (REE) modulation
- Lipid profile optimization
Potential Benefits
- Unprecedented fat mass reduction
- Rapid clearance of hepatic steatosis (liver fat)
- Sustained appetite suppression
- Increased resting metabolic rate
- Improved insulin sensitivity
Research Dosing Guidelines
For research purposes only. Not for human consumption.
Typical Dose
1-12 mg
Frequency
Once weekly
Duration
16-48 weeks
Administration
Subcutaneous injection
Research subjects usually start at 1mg or 2mg weekly for 4 weeks to assess tolerance before stepping up to 4mg. The glucagon activity means transient heart rate spikes are more common here than with tirzepatide. If you rush the titration schedule, the GI distress will absolutely wreck you.
Reconstitution Calculator
U-100 Insulin Syringe
0.0 units
2500 mcg/ml
0.0004 ml
0.0 IU
5000
For research and educational purposes only. Always follow proper reconstitution and sterile handling protocols.
Triple Agonism Explained: GLP-1 + GIP + Glucagon
Retatrutide's triple receptor mechanism represents the current pinnacle of incretin-based metabolic therapy. Each receptor contributes distinct and complementary metabolic effects.
Three-Receptor Breakdown
| Receptor | Primary Effect | Contribution to Weight Loss |
|---|---|---|
| GLP-1 | Appetite suppression, insulin sensitization | Reduces caloric intake by ~25-35% |
| GIP | Adipose tissue remodeling, enhanced insulin response | Improves fat tissue metabolism directly |
| Glucagon | Increases energy expenditure, hepatic fat oxidation | Burns more calories at rest + clears liver fat |
The glucagon component is what produces the ~24% weight loss ceiling — subjects aren't just eating less, they're burning significantly more energy. The trade-off is an elevated resting heart rate (typically 5-10 bpm) driven by the glucagon-mediated thermogenic effect, which stabilizes over time in most subjects.
Potential Side Effects
- Severe nausea if titrated too quickly
- Elevated resting heart rate (usually peaks around 24 weeks)
- Severe gastrointestinal distress (diarrhea or constipation)
- Significant lean tissue loss if subjects aren't resistance training
Storage Requirements
Store lyophilized powder at -20°C for long-term preservation. Keep reconstituted vials strictly at 2-8°C and use within 30 days.
Research References
- [1]Triple-Hormone-Receptor Agonist Retatrutide for Obesity (2023)Strong Evidence Population: Adults with obesity (BMI ≥30) without diabetes (n=338)
Retatrutide caused up to 24.2% weight loss at 48 weeks at the highest dose (12 mg) in adults with obesity.
Limitations: 48-week Phase II trial; Phase III confirmatory data still pending
- [2]Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes (2023)Strong Evidence Population: Adults with T2D inadequately controlled on metformin (n=281)
Demonstrated robust reductions in HbA1c and body weight with an acceptable safety profile in T2D patients.
Limitations: 36-week Phase II; optimal dose for T2D vs obesity may differ
- [3]LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist (2022)Emerging Evidence Population: Diet-induced obese mice and non-human primates
Showed that the triple agonism drives superior weight loss and energy expenditure increases compared to dual or single agonists in murine models.
Limitations: Preclinical models; glucagon receptor safety concerns require long-term human monitoring
Frequently Asked Questions
What is Retatrutide?
Retatrutide is a highly modified 39-amino-acid peptide that acts as an agonist at the GLP-1, GIP, and Glucagon receptors. Researchers developed it to maximize metabolic output, combining the appetite suppression of standard incretins with the fat-burning effects of glucagon.
What are the potential research benefits of Retatrutide?
Clinical trials show it drives massive fat loss, improves insulin sensitivity, and dramatically reduces liver fat. The addition of glucagon receptor agonism specifically increases resting metabolic rate, forcing the body to burn more calories even at rest.
How is Retatrutide typically dosed in research?
Research protocols dose retatrutide once weekly via subcutaneous injection, starting at 1-2 mg for the first four weeks. Doses are then titrated upward in 2mg increments every four weeks based on subject tolerance, eventually capping at 8-12 mg.
What are the side effects of Retatrutide?
The main hurdles are gastrointestinal—nausea, vomiting, and diarrhea are very common, especially during dose escalations. Because of the glucagon activity, researchers also frequently observe a noticeable increase in resting heart rate that typically normalizes over time.
How should Retatrutide be stored?
Keep lyophilized powder in the freezer at -20°C to maintain stability. Once reconstituted, store the vial in the refrigerator at 2-8°C and discard after 30 days.
Ready to Purchase Retatrutide?
Get the highest quality Retatrutide from our recommended vendor with 99%+ purity guaranteed.
Buy at Peptide PalaceRelated Topics
Peptide Hormones and Their Functions
Peptide hormones are hydrophilic signaling molecules that bind cell surface receptors, triggering intracellular cascades via second messengers like cAMP and calcium.
Therapeutic Applications of Peptides
Therapeutic peptides occupy the pharmacological space between small molecules and biologics, offering high selectivity for protein-protein interactions with lower immunogenicity.
Safety & Reference
Related Peptides
Semaglutide
Semaglutide Acetate
Semaglutide is a GLP-1 receptor agonist that mimics the effects of the naturally occurring hormone GLP-1. It has gained significant attention for its powerful effects on appetite regulation and blood sugar control, leading to substantial weight loss in research subjects.
Learn MoreTirzepatide
Tirzepatide
Tirzepatide is a dual GIP and GLP-1 receptor agonist, representing a new class of medications for metabolic conditions. It has shown remarkable efficacy in weight loss and glycemic control studies, often surpassing the results of single-receptor agonists.
Learn MoreCagrilintide
Cagrilintide (NN9838)
Just when we thought GLP-1 agonists had peaked, researchers started looking at amylin. Cagrilintide is a long-acting amylin analogue developed by Novo Nordisk specifically to run alongside semaglutide. The combination, dubbed CagriSema in clinical trials, produces weight loss numbers that straight-up rival bariatric surgery. It attacks appetite from a completely different neurological angle than tirzepatide or semaglutide, making it the ultimate plateau-breaker for subjects who have stalled on standard therapies.
Learn MoreMazdutide
Mazdutide (IBI362 / LY3305677)
Developed originally by Eli Lilly and advanced by Innovent Biologics, Mazdutide (IBI362) functions as a dual GLP-1 and glucagon receptor agonist. Think of it as a synthetic, long-acting version of oxyntomodulin, a naturally occurring hormone that kills appetite while actively burning stored fat. The clinical data out of China right now is staggering, especially regarding its ability to aggressively clear out liver fat while matching or beating the weight loss seen with standard single-agonist drugs.
Learn More